All Clinical Trials
Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.
322 trials found
Drug |
NCT# |
||
|---|---|---|---|
| neoBOMB1 | [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay) | 1 |
|
| Imatinib | 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk | 2 |
|
| PLX3397 + Pembrolizumab | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | 1 |
|
| Sunitinib | A Continuation Study To Provide Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. | 3 |
|
| MEDI-573 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors | 1 |
|
| Imatinib + BKM120 | A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients | 1 |
|
| Imatinib + BYL719 | A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | 1 |
|
| IDRX-42 | A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1] | 1 |
|
| Imatinib, Nilotinib | A Global Imatinib and Nilotinib Pregnancy Exposure Registry | ||
| R1507 | A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors | 1 |
|
| Sunitinib + Regorafenib | A Non-randomized, Open-label, Single-center Phase Ib Study of Short Cycles of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors: SURE Trial | 1 |
|
| Multi-bacteria vaccine (MBV) | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen. | 1 |
|
| Cobimetinib + MPDL3280A | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors | 1 |
|
| XL820 | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib | 2 |
|
| Ponatinib (Iclusig) | A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | 2 |
|
| Ripretinib | A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT) | 3 |
|
| Masitinib, (AB1010) | A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment | 3 |
|
| IPI-493 | A Phase I Dose Escation Study of IPI-493 | 1 |
|
| SF1126 | A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor, Given Twice Weekly by IV Infusion to Patients With Advanced or Metastatic Tumors | 1 |
|
| Bortezomib + Sunitinib | A Phase I Trial of Bortezomib and Sunitinib | 1 |
|
| BEZ235 | A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | 1 |
|
| BGT226 | A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer | 1 |
|
| Regorafenib + Avelumab | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | 1/2 |
|
| Sunitinib | A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) | 1 |
|
| Imatinib + PKC412 | A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM | 1 |
|
| BKM120 | A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies | 1 |
|
| LBH589 | A Phase IA, two-arm, multi-center, dose escalating study of LBH589 administered intravenously on two dose schedules in adult patients with advanced solid tumors & non-Hodgkin’s lymphoma. | 1 |
|
| MEK162 + BYL719 | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | 2 |
|
| IMC-A12 | A Phase II Study of IMC-A12 in Children With Relapsed/Refractory Solid Tumors | 2 |
|
| Masitinib, (AB1010) | A phase II study to compare efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in treatment of patients with gastro-intestinal stromal tumor resistant to imatinib | 2 |
|
| Guadecitabine | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer | 2 |
|
| CS-1008 and Imatinib or Sunitinib | A Pilot Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5, Alone or In Combination with Imatinib Mesylate or Sunitinib Malate In Subjects with Advanced Gastrointestinal Stromal Tumors | 1 |
|
| Imatinib | A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors | 2 |
|
| Imatinib + Atezolizumab | A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST) | 2 |
|
| Imatinib + Regorafenib | A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST) | 2 |
|
| Imatinib | A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment | ||
| QINLOCK Ripretinib DCC-2618 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | 1 |
|
| GDC-0980 | A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | 1 |
|
| GDC-0980 | A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | 1 |